Efficacy, Adherence and Side Effects of PrEP for HIV-1 Prevention

Wanyi Fang, Bongani I. Mphoyi, Dineo R. Motake, Jianxin Liu, Wenshuang Li, Fanghua Mei, Shenghan Lai and Jun Wang

International Journal of Biology, 2021, vol. 11, issue 4, 80

Abstract: Each year, approximately two million new HIV infections are reported worldwide. About one decade ago, a company called Gilead Sciences Inc. discovered a new HIV prevention method named as pre-exposure prophylaxis (PrEP). When high adherence was kept among high-risk population, PrEP efficacy could reach as high as 99%. However, the adverse effects have been reported from time to time, including low efficacy in certain cases, adherence difficulties and medicinal side effects. In this review, we would summarize the progress of PrEP since its introduction in order to provide insights for HIV prevention.

Date: 2021
References: View references in EconPapers View complete reference list from CitEc
Citations:

Downloads: (external link)
https://ccsenet.org/journal/index.php/ijb/article/download/0/0/40525/41751 (application/pdf)
https://ccsenet.org/journal/index.php/ijb/article/view/0/40525 (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:ibn:ijbjnl:v:11:y:2021:i:4:p:80

Access Statistics for this article

More articles in International Journal of Biology from Canadian Center of Science and Education Contact information at EDIRC.
Bibliographic data for series maintained by Canadian Center of Science and Education ().